Vortrag
ADUCANUMAB TITRATION DOSING REGIMEN: 24-MONTH ANALYSIS FROM PRIME, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B STUDY IN PATIENTS WITH PRODROMAL OR MILD ALZHEIMER’S DISEASE
Speaker
Datum:
15.04.2018 ,
Zeit:
12:25
|
Thema: Internisten und das (zentrale) Nervensystem
Details